Markets | |
Each investor has their own unique set of goals that are based on their own personality and risk tolerance preferences. What works for one person might seem a little too risky for another. That’s why it’s so important to do your research and put the work in to create an investment stra... Read the Full Story |
|
From Our Partners | | Marc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are triggering a historic wealth transfer already underway in 2026. Household names like Intuit (-57%), Boston Scientific (-49%), and Tractor Supply (-40%) are cratering, while lesser-known companies like Sandisk (+573%) and Rackspace (+444%) surge.
Chaikin has identified specific stocks he believes investors should sell before they fall further - and the names may surprise you. He's also pinpointing a company tapped as Nvidia's self-driving partner and a potential AI megadeal that could split into three high-growth stocks.
Stream his free presentation to get every buy and sell recommendation with no membership or credit card required. | | Watch Marc Chaikin's free presentation and get his full buy-and-sell list today |
|
Markets | |
It could be forgiven, that some might think that Tesla (NASDAQ: TSLA) was little more than a big pile of pie-in-the-sky nonsense. Yet it seems, these days, that we hear a lot of positive buzz around this maker of electric vehicles that implores we take this company seriously. One more brick in the... Read the Full Story |
|
Markets | | The Labor Market Is Driving Our Economy And Coming To A Boil
The labor markets were one of the most closely watched segment of our economy in 2019. Despite all the naysaying, the labor market ended the year on the most solid footing its been on in the history of the U.S. The size of the labor force... Read the Full Story |
|
From Our Partners | | Hedge funds are rotating out of AI hype and into the hardware layer powering it. New research identifies three profitable U.S. infrastructure companies leading this shift.
One just posted 76% year-over-year data-center growth. Another holds a $12 billion backlog from global hyperscalers. A third is generating 59%+ gross margins on next-gen chips. | | Access the full analysis, price setups, and catalysts now |
|
Markets | | Industrials Will Lead The Market In 2020
With the end of the year just around the corner, it’s past time to think about positioning for 2020. When it comes to earnings power in 2020, the Industrial sector is going to be the market leader and that is where I like my money to be. To be clear, w... Read the Full Story |
|
Markets | |
It's one of the biggest tech stocks there is, and a come-from-behind underdog that turned into a behemoth over the course of the 2010s. It's fundamentally shaken up not only technology, but the arts as well, and even the entire field of e-commerce owes a lot to it. It's Apple (NASDAQ:AAPL), and it... Read the Full Story |
|
From Our Partners | | Barrick Mining has spent decades building one of Nevada's richest gold districts, anchored by Fourmile, Goldrush, and Cortez Hills, deposits that could hold up to 60 million ounces of gold.
One overlooked explorer controls 142 claims bordering Fourmile and sitting less than a mile from Goldrush. New geological modeling aims to reveal what's beneath this largely untested ground, while a planned 5% royalty spin-off could give shareholders a separate stake in the project. | | Read the full report before the next catalyst hits |
|
Markets | | Shares of Rite Aid (NYSE: RAD) have been giving investors heart attacks of pleasure and of fear in the past couple of trading sessions as they’ve made double-digit percentage jumps up and down.
The volatility started on December 19th when the company released its Q3 earnings report. At $0.54,... Read the Full Story |
|
Markets | | Earnings Growth And Dividends In Uncertain Times
Nomura Instinet analyst Anindya Das has gotten bullish on Goodyear Tire (GT). The analyst has initiated coverage on the world’s largest tire company with a buy rating implying a 30% upside to today’s prices. The $20 target would mark a 10... Read the Full Story |
|
Markets | | If Wall Street can hold the line for the next two trading days, the stock market will lock in its best year in over 20 years. Having already rallied 175% from January 2009 through December 2018, you’d have been forgiven for thinking the S&P 500 might start topping out after one of the most... Read the Full Story |
|
Markets | |
There are many oil companies around the world that trade their shares on a stock market. With all of the different choices, it can be tough knowing which stock is the best for your portfolio. Before making a decision, it can be helpful to examine the top-performing oil companies.
Top Oil Companie... Read the Full Story |
|
Markets | |
One of the best aspects of becoming a trader is the sheer amount of different opportunities out there that can allow you to be profitable. The most successful traders are constantly learning new things and seeking out different ways to make money in the market. If you aren’t familiar with tr... Read the Full Story |
|
The Early Bird Stock Of The Day Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia. | | View Today's Stock Pick |
|
